SubramanianSTumlinJBapatBZyczynskiT. Economic burden of contrast-induced nephropathy: implications for prevention strategies. J Med Econ. 2007;10:119–34.
2.
KayaAKayaYTopcuS, et al.Neutrophil-to-lymphocyte ratio predicts contrast-induced nephropathy in patients undergoing primary percutaneous coronary intervention. Angiology. 2014;65:51–56.
3.
ZorluCKoseogluC. Comparison of the relationship between inflammatory markers and contrast-induced nephropathy in patients with acute coronary syndrome after coronary angiography. Angiology. 2020;71:249–55.
4.
HeHChenXRChenYQNiuTSLiaoYM. Prevalence and predictors of contrast-induced nephropathy (CIN) in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI): a meta-analysis. J Interv Cardiol. 2019;2019:2750173.
5.
AzzaliniLSpagnoliVLyHQ. Contrast-induced nephropathy: from pathophysiology to preventive strategies. Can J Cardiol. 2016;32:247–55.
OksuzFElcikDYarliogluesM, et al.The relationship between lymphocyte-to-monocyte ratio and saphenous vein graft patency in patients with coronary artery bypass graft. Biomark Med. 2017;11:867–76.